4.8 Article

Biodegradable silicon nanoneedles for ocular drug delivery

期刊

SCIENCE ADVANCES
卷 8, 期 13, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abn1772

关键词

-

资金

  1. NIH National Eye Institute (NEI) [R01EY033000]
  2. National Science Foundation (NSF) Chemical, Bioengineering, Environment, and Transport Systems (CBET) [2032529]
  3. NIH NEI [1K08EY027458, 1R41EY031219]
  4. Research to Prevent Blindness
  5. NEI [P30EY007003]
  6. National Research Foundation of Korea (NRF) - Ministry of Science and ICT of Korea [NRF-2018K1A3A1A32055469]
  7. MOTIE (Ministry of Trade, Industry, and Energy) in Korea [P0008748]
  8. Directorate For Engineering
  9. Div Of Chem, Bioeng, Env, & Transp Sys [2032529] Funding Source: National Science Foundation
  10. National Research Foundation of Korea [2018K1A3A1A32055469] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

This article introduces a unique platform for ocular drug delivery, which integrates silicon nanoneedles with tear-soluble contact lenses. The platform enables painless and long-term sustained delivery of ocular drugs, and has shown effectiveness in treating chronic ocular diseases.
Ocular drug delivery remains a grand challenge due to the complex structure of the eye. Here, we introduce a unique platform of ocular drug delivery through the integration of silicon nanoneedles with a tear-soluble contact lens. The silicon nanoneedles can penetrate into the cornea in a minimally invasive manner and then undergo gradual degradation over the course of months, enabling painless and long-term sustained delivery of ocular drugs. The tear-soluble contact lens can fit a variety of corneal sizes and then quickly dissolve in tear fluid within a minute, enabling an initial burst release of anti-inflammatory drugs. We demonstrated the utility of this platform in effectively treating a chronic ocular disease, such as corneal neovascularization, in a rabbit model without showing a notable side effect over current standard therapies. This platform could also be useful in treating other chronic ocular diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据